Studies from Karolinska Institute Further Understanding of Diabetes (Long-Term Metformin Usage and Cognitive Function among Older Adults with Diabetes)
By a News Reporter-Staff News Editor at Diabetes Week -- Investigators publish new report on Diabetes. According to news reporting from Stockholm, Sweden, by NewsRx journalists, research stated, "Evidence strongly supports the important role of insulin resistance in cognitive decline and dementia and suggests that insulin sensitizers may protect against cognitive decline in diabetic and pre-diabetic individuals. Inconclusive results have been reported in clinical trials of rosiglitazone, an insulin sensitizer that also increases cardiovascular mortality risks."
The news correspondents obtained a quote from the research from Karolinska Institute, "No study has yet reported a protective cognitive effect of metformin, an insulin-sensitizing biguanide widely used in diabetic patients. We studied 365 older persons aged 55 and over in the population-based Singapore Longitudinal Aging Study with diabetes who were followed up over 4 years. The odds ratios (OR) of association of metformin use (n=204) versus non-use (n=161) with cognitive impairment (Mini-Mental State Exam <= 23), and by duration: up to 6 years (n=114) and more than 6 years (n=90) were evaluated in cross-sectional and longitudinal multivariate analyses. Controlling for age, education, diabetes duration, fasting blood glucose, vascular and non-vascular risk factors, metformin use showed a significant inverse association with cognitive impairment in longitudinal analysis (OR=0.49, 95% CI 0.25-0.95). Metformin use showed significant linear trends of association across duration of use in cross-sectional and longitudinal analyses (p=0.018 and p=0.002, respectively), with use for more than 6 years significantly associated with lowest risk of cognitive impairment in both cross-sectional analysis (OR=0.30, 95% CI 0.11-0.80) and in longitudinal analysis (OR=0.27, 95% CI 0.12-0.60). No significant interactive effects of metformin use with APOE-epsilon 4, depression, or fasting glucose level were observed. Among individuals with diabetes, long-term treatment with metformin may reduce the risk of cognitive decline."
According to the news reporters, the research concluded: "Further studies should establish the role of hyperglycemia and insulin resistance, and the protective role of metformin in the risk of cognitive decline and dementia."
For more information on this research see: Long-Term Metformin Usage and Cognitive Function among Older Adults with Diabetes. Journal of Alzheimers Disease, 2014;41(1):61-68. Journal of Alzheimers Disease can be contacted at: Ios Press, Nieuwe Hemweg 6B, 1013 Bg Amsterdam, Netherlands (see also Diabetes).
Our news journalists report that additional information may be obtained by contacting T.P. Ng, Karolinska Inst, Dept. of Neurobiol, Care Sci & Soc NVS, Stockholm, Sweden. Additional authors for this research include L. Feng, K.B. Yap, T.S. Lee, C.H. Tan and B. Winblad.
Keywords for this news article include: Sweden, Europe, Diabetes, Stockholm, Proinsulin, Endocrinology, Peptide Hormones
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC